Sionna Therapeutics (NASDAQ:SION) Lowered to Hold Rating by Freedom Capital

Freedom Capital lowered shares of Sionna Therapeutics (NASDAQ:SION) from a strong-buy rating to a hold rating in a report published on Wednesday,Zacks.com reports.

Other equities research analysts have also recently issued research reports about the stock. UBS Group reaffirmed a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Lifesci Capital raised shares of Sionna Therapeutics to a “strong-buy” rating in a report on Wednesday, February 25th. Citigroup started coverage on Sionna Therapeutics in a report on Tuesday, February 24th. They set an “outperform” rating for the company. Wedbush assumed coverage on Sionna Therapeutics in a research report on Tuesday, May 5th. They set an “outperform” rating and a $53.00 target price on the stock. Finally, Guggenheim lifted their price target on Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Sionna Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $53.22.

Sionna Therapeutics Trading Up 4.8%

SION stock opened at $39.50 on Wednesday. The stock has a market cap of $1.78 billion, a PE ratio of -20.47 and a beta of 1.35. The company has a 50-day moving average price of $39.56 and a 200 day moving average price of $39.56. Sionna Therapeutics has a 12 month low of $12.42 and a 12 month high of $48.44.

Sionna Therapeutics (NASDAQ:SION) last issued its earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). Sell-side analysts forecast that Sionna Therapeutics will post -2.57 EPS for the current year.

Insider Buying and Selling

In other Sionna Therapeutics news, Director Peter A. Thompson sold 235,863 shares of Sionna Therapeutics stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total value of $10,528,924.32. Following the transaction, the director directly owned 3,247,025 shares of the company’s stock, valued at approximately $144,947,196. The trade was a 6.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 235,863 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32. Following the transaction, the director directly owned 3,247,025 shares in the company, valued at approximately $144,947,196. The trade was a 6.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 1,717,760 shares of company stock worth $77,562,902. Insiders own 3.90% of the company’s stock.

Institutional Trading of Sionna Therapeutics

Institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. acquired a new position in Sionna Therapeutics during the 3rd quarter valued at about $30,000. BNP Paribas Financial Markets acquired a new stake in Sionna Therapeutics in the second quarter worth about $31,000. GF Fund Management CO. LTD. purchased a new stake in shares of Sionna Therapeutics during the fourth quarter worth about $36,000. Balyasny Asset Management L.P. acquired a new position in shares of Sionna Therapeutics during the fourth quarter valued at about $58,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Sionna Therapeutics during the fourth quarter valued at about $89,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.